Genevec Contra

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Genevec Contra and buy or sell other stocks, ETFs, and their options commission-free!

About GNVC

GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. 

CEO
Douglas J. Swirsky, MBA, CPA
CEODouglas J. Swirsky, MBA, CPA
Employees
Employees
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
1992
Founded1992
Employees
Employees

GNVC Key Statistics

Market cap
16.36M
Market cap16.36M
Price-Earnings ratio
-1.97
Price-Earnings ratio-1.97
Dividend yield
Dividend yield
Average volume
8.00K
Average volume8.00K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$10.44
52 Week high$10.44
52 Week low
$2.70
52 Week low$2.70

Stock Snapshot

The current Genevec Contra(GNVC) stock price is $7.19, with a market capitalization of 16.36M. The stock trades at a price-to-earnings (P/E) ratio of -1.97.

During the trading day, Genevec Contra(GNVC) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for Genevec Contra(GNVC) stock has reached 0, versus its average volume of 8K.

The stock's 52-week range extends from a low of $2.70 to a high of $10.44.

The stock's 52-week range extends from a low of $2.70 to a high of $10.44.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.